er mutations. Combining whole genome sequencing, exome sequencing, and RNA expression analysis—what Washington University pro- fessor of genetics and Genome Institute co-director Elaine Mardis calls the “Maserati approach”—the team compares a comprehensive genetic profile against a database of drugs that target spe